Altre lingue Hanall Biopharma Co., Ltd.

Azioni

A009420

KR7009420001

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 10/05/2024			Variaz. 5gg	Var. 1 gen.
33.950 ^KRW	-0,73%		-4,77%	-23,36%

03/05	HanAll Biopharma annuncia l'avvio dello studio di Fase III VELOS-4, randomizzato, in doppia maschera, controllato con veicolo, che valuta Tanfanercept per il trattamento della malattia dell'occhio secco	CI
06/03	Hanall Biopharma Co., Ltd. Riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	03/05
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	13/06/23
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	13/06/23
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	12/06/23
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01/05/23
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth	30/03/23
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program	16/03/23
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities	13/02/23
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.	13/02/23
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.	10/02/23
Immune Thrombocytopenia Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain	09/12/22
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update	16/11/22
HanAll Biopharma's Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China	11/10/22
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11/10/22
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04/10/22
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update	01/08/22
Hanall Biopharma : Decision on Disposal of Treasury Stock	23/06/22
Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.	15/06/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hanall Biopharma Co., Ltd.

Azioni

A009420

KR7009420001

Altre lingue

Filtri